NASDAQ:ACAD
ACADIA Pharmaceuticals Inc. Stock News
$17.08
+0.0300 (+0.176%)
At Close: May 02, 2024
HAGENS BERMAN Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact the Firm, Securities Fraud Class Action Filed
06:30pm, Thursday, 20'th May 2021
San Francisco, California--(Newsfile Corp. - May 20, 2021) - Hagens Berman urges Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now. Class Period:
NEW YORK, May 18, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Acadia Pharmaceuticals Inc. ("Acadia" or the "Company")(NASDAQ: ACAD) and certain of i
San Francisco, California--(Newsfile Corp. - May 17, 2021) - Hagens Berman urges Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now.Class Period: Ju
New York, New York--(Newsfile Corp. - May 13, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Aca
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Acadia Pharmaceuticals Inc. (ACAD)
11:06am, Thursday, 13'th May 2021
LOS ANGELES, May 13, 2021 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming June 18, 2021 deadline to file a lead plaintiff motion in the case filed on behalf
NEW YORK, May 13, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Acadia Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD) and certain of
Los Angeles, California--(Newsfile Corp. - May 12, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ACADIA Pharmaceutical
New York, New York--(Newsfile Corp. - May 11, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Aca
New York, New York--(Newsfile Corp. - May 6, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Acad
ACADIA (ACAD) Q1 Earnings Beat, Revenues Fall Shy of Estimates
08:16am, Thursday, 06'th May 2021
ACADIA's (ACAD) loss narrows in the first quarter of 2021 while its revenues miss the mark. Robust Nuplazid performance drives the top line year over year.
New York, New York--(Newsfile Corp. - May 6, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) a
ACADIA Pharmaceuticals, Inc. (ACAD) CEO Stephen Davis on Q1 2021 Results - Earnings Call Transcript
11:45pm, Wednesday, 05'th May 2021
ACADIA Pharmaceuticals, Inc. (ACAD) CEO Stephen Davis on Q1 2021 Results - Earnings Call Transcript
Acadia Pharmaceuticals (ACAD) Reports Q1 Loss, Lags Revenue Estimates
07:10pm, Wednesday, 05'th May 2021
Acadia (ACAD) delivered earnings and revenue surprises of 20.75% and -5.63%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
New York, New York--(Newsfile Corp. - May 5, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Acad
San Francisco, California--(Newsfile Corp. - May 5, 2021) - Hagens Berman urges Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now. Class Period: Ju
